|
1
|
Di Maio M, Daniele B and Perrone F:
Targeted therapies: Role of sorafenib in HCC patients with
compromised liver function. Nat Rev Clin Oncol. 6:505–506. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rudalska R, Dauch D, Longerich T, McJunkin
K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun
A, et al: In vivo RNAi screening identifies a mechanism of
sorafenib resistance in liver cancer. Nat Med. 20:1138–1146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z,
Chen EB, Fan J, Cao Y, Dai Z and Zhou J: Tumor-associated
neutrophils recruit macrophages and T-regulatory cells to promote
progression of hepatocellular carcinoma and resistance to
sorafenib. Gastroenterology. 150:1646–1658.e17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goodman A, Patel SP and Kurzrock R:
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev
Clin Oncol. 14:203–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Massard C, Gordon MS, Sharma S, Rafii S,
Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE,
et al: Safety and efficacy of durvalumab (MEDI4736), an
anti-programmed cell death ligand-1 immune checkpoint inhibitor, in
patients with advanced urothelial bladder cancer. J Clin Oncol.
34:3119–3125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bishop JL, Sio A, Angeles A, Roberts ME,
Azad AA, Chi KN and Zoubeidi A: PD-L1 is highly expressed in
Enzalutamide-resistant prostate cancer. Oncotarget. 6:234–242.
2015.PubMed/NCBI
|
|
10
|
Yan F, Pang J, Peng Y, Molina JR, Yang P
and Liu S: Elevated cellular PD1/PD-L1 expression confers acquired
resistance to cisplatin in small cell lung cancer cells. PLoS One.
11:e01629252016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu H, Bengsch F, Svoronos N, Rutkowski
MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE,
Conejo-Garcia JR, et al: BET Bromodomain inhibition promotes
anti-tumor immunity by suppressing PD-L1 expression. Cell Rep.
16:2829–2837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Casey SC, Tong L, Li Y, Do R, Walz S,
Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, et al: MYC
regulates the antitumor immune response through CD47 and PD-L1.
Science. 352:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lo J, Lau EY, Ching RH, Cheng BY, Ma MK,
Ng IO and Lee TK: Nuclear factor kappa B-mediated CD47
up-regulation promotes sorafenib resistance and its blockade
synergizes the effect of sorafenib in hepatocellular carcinoma in
mice. Hepatology. 62:534–545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baylin SB: DNA methylation and gene
silencing in cancer. Nat Clin Pract Oncol. 2:(Suppl 1). S4–S11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esteller M, Fraga MF, Paz MF, Campo E,
Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J, et al:
Cancer epigenetics and methylation. Science. 297:1807–1808. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spinzi G and Paggi S: Sorafenib in
advanced hepatocellular carcinoma. N Engl J Med. 359:2497–2498;
author reply 2498–2499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Li J, Huang T, Duan S, Dai D,
Jiang D, Sui X, Li D, Chen Y, Ding F, et al: Meta-analysis of DNA
methylation biomarkers in hepatocellular carcinoma. Oncotarget.
7:81255–81267. 2016.PubMed/NCBI
|
|
21
|
Huang J, Wang Y, Guo Y and Sun S:
Down-regulated microRNA-152 induces aberrant DNA methylation in
hepatitis B virus-related hepatocellular carcinoma by targeting DNA
methyltransferase 1. Hepatology. 52:60–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Ruan Y, Wang X, Min L, Shen Z, Sun
Y and Qin X: BAY 11–7082, a nuclear factor-κB inhibitor, induces
apoptosis and S phase arrest in gastric cancer cells. J
Gastroenterol. 49:864–874. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Villanueva A, Lachenmayer A and
Finn RS: Advances in targeted therapies for hepatocellular
carcinoma in the genomic era. Nat Rev Clin Oncol. 12:4362015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST,
Yen CJ, Yang CY, Sung SY and Su JL: Angiopoietin-like protein 1
antagonizes MET receptor activity to repress sorafenib resistance
and cancer stemness in hepatocellular carcinoma. Hepatology.
64:1637–1651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z,
Wu Y, Wang W, Wu J, Tao S, Yang X, et al: PROX1 promotes
hepatocellular carcinoma proliferation and sorafenib resistance by
enhancing β-catenin expression and nuclear translocation. Oncogene.
34:5524–5535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin B and Robertson KD: DNA
methyltransferases, DNA damage repair, and cancer. Adv Exp Med
Biol. 754:3–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Min HY, Lee SC, Woo JK, Jung HJ, Park KH,
Jeong HM, Hyun SY, Cho J, Lee W, Park JE, et al: Essential role of
DNA methyltransferase 1-mediated transcription of insulin-like
growth factor 2 in resistance to histone deacetylase inhibitors.
Clin Cancer Res. 23:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang C and Gong F: DNA methyltransferase
1: A potential gene therapy target for hepatocellular carcinoma?
Oncol Res Treat. 39:448–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Welch JS, Petti AA, Miller CA, Fronick CC,
O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon
B, et al: TP53 and decitabine in acute myeloid leukemia and
myelodysplastic syndromes. N Engl J Med. 375:2023–2036. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duncavage EJ, Uy GL, Petti AA, Miller CA,
Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, et
al: Mutational landscape and response are conserved in peripheral
blood of AML and MDS patients during decitabine therapy. Blood.
129:1397–1401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nagaya T, Nakamura Y, Sato K, Harada T,
Choyke PL, Hodge JW, Schlom J and Kobayashi H: Near infrared
photoimmunotherapy with avelumab, an anti-programmed death-ligand 1
(PD-L1) antibody. Oncotarget. 8:8807–8817. 2017.PubMed/NCBI
|
|
33
|
Zhang Q, Wang HY, Woetmann A, Raghunath
PN, Odum N and Wasik MA: STAT3 induces transcription of the DNA
methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood.
108:1058–1064. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang WB, Yen ML, Liu KJ, Hsu PJ, Lin MH,
Chen PM, Sudhir PR, Chen CH, Chen CH, Sytwu HK, et al:
Interleukin-25 mediates transcriptional control of PD-L1 via STAT3
in multipotent human mesenchymal stromal cells (hMSCs) to suppress
Th17 responses. Stem Cell Rep. 5:392–404. 2015. View Article : Google Scholar
|
